# Hypercholesterolaemia: optimal treatment by next-generation drugs?

**Authors:** E.E. van der Wall

PMC · DOI: 10.1007/s12471-015-0741-2 · Netherlands Heart Journal · 2015-09-01

## Full-text entities

- **Genes:** COG2 (component of oligomeric golgi complex 2) [NCBI Gene 22796] {aka CDG2Q, LDLC}, PCSK9 (proprotein convertase subtilisin/kexin type 9) [NCBI Gene 255738] {aka FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}
- **Diseases:** cerebrovascular accident (MESH:D020521), Familial hypercholesterolaemia (MESH:D000073376), heart disease (MESH:D006331), unstable angina (MESH:D000789), autosomal dominant genetic disorder (MESH:D030342), homozygous autosomal dominant hypercholesterolaemia (MESH:D000090542), cardiovascular disease (MESH:D002318), acute coronary syndromes (MESH:D054058), myocardial infarction (MESH:D009203)
- **Chemicals:** cholesterol (MESH:D002784), ezetimibe (MESH:D000069438), Alirocumab (MESH:C571059), Evolocumab (MESH:C577155)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4580667/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC4580667/full.md

---
Source: https://tomesphere.com/paper/PMC4580667